The prevena¿ dressing lot number was not provided and was not returned; therefore, a device history record review and device evaluation could not be performed.Based on the information provided, it cannot be determined that the alleged fungal infection is related to the prevena¿ dressing.Multiple unsuccessful attempts were made for additional clinical and device information.It is unknown if and what medical or surgical intervention was required.Device labeling, available in print and online, states: warnings: infected wounds: as with any wound treatment, clinicians and patients/caregivers should frequently monitor the patient's wound, periwound tissue and exudate for signs of infection, worsening infection or other complications.Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound or periwound area, purulent discharge or strong odor.Infection can be serious, and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and/or fatal injury.Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever, refractory and/or orthostatic hypotension or erythroderma (a sunburn-like rash).Silver in the interface layer of prevena¿ dressing is not intended to treat infection, but to reduce bacterial colonization in the fabric.If infection develops, prevena plus¿ therapy should be discontinued until the infection is treated.
|